Novavax’s Latecomer COVID-19 Vaccine Impresses With 90% Efficacy Result
Role As Booster Could Be Key
Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.
You may also be interested in...
Novavax’s COVID-19 Shot Finally Authorized In US, But Could Miss Out Again On Bivalent Booster
A protein-based vaccine for COVID-19 reaches the US at last, but Novavax looks set miss out once again as the fall deadline for BA.4/5 variant-targeting vaccines approaches.
To Boost Or Not To Boost? Pfizer, FDA, And The COVID Vaccine Communication Challenge
Pfizer’s bid for third dose appears to get pushback from the US government, but reticence about the booster may reflect PR considerations more than any fundamental concern about the vaccine.
To Boost Or Not To Boost? Pfizer At Odds With US FDA
US regulators indicate that authorizing booster shots is not a priority - but Pfizer still plans to seek an EUA in the fall.